

Buprofezin: Non-renewal of EU approval

Published by AGRINFO on 13 Jul 2026

Draft Commission Implementing Regulation concerning the non-renewal of the approval of the active substance buprofezin

What is changing and why?

The European Commission does not intend to renew its approval for the active substance buprofezin because concerns have been identified about its endocrine-disrupting properties.

As the EU maximum residue levels (MRLs) for buprofezin are already set at the limit of determination (LOD – the lowest level that can be detected using the most modern and reliable analytical methods), this should have no impact on exports to the EU.

Actions

Competent authorities of countries that are members of the World Trade Organization can submit comments on the EU's proposal by emailing the [EU TBT Enquiry Point](#) until **31 August 2026**.

Timeline

This Regulation is expected to apply from November 2026.

Existing EU Member State authorisations of products containing buprofezin will have to be withdrawn within 6 months after the Regulation enters into force.

For more information see the [full record](#) on the AGRINFO website – where you can also view the latest [AGRINFO Update](#) newsletters and [search](#) the database.

Disclaimer: *Under no circumstances shall COLEAD be liable for any loss, damage, liability or expense incurred or suffered that is claimed to have resulted from the use of information available on this website or any link to external sites. The use of the website is at the user's sole risk and responsibility. This information platform was created and maintained with the financial support of the European Union. Its contents do not, however, reflect the views of the European Union.*